I-Mab (NBP) Stock Price, News & Analysis

Company Overview

I-Mab is a clinical-stage biotechnology company focused on the discovery, development and commercialization of biologic therapies for oncology and immunology indications. The company concentrates on advancing antibody-based therapeutics and other protein biologics intended to modulate the immune system to treat cancer and autoimmune or inflammatory diseases. Its development activities span preclinical research through late-stage clinical trials, with an emphasis on creating targeted, differentiated molecules designed to address unmet medical needs.

Headquartered in China with global development activities, I-Mab operates research and development facilities and engages with clinical investigators and regulatory authorities across multiple geographies to support global clinical programs. The company’s strategy includes progressing internally discovered assets toward registration and exploring partnerships or licensing arrangements to expand commercial and geographic reach.

I-Mab’s capabilities are built around biologics research, including antibody discovery and protein engineering, translational development and clinical operations. The organization pursues a pipeline approach that balances oncology and immunology projects, aiming to generate data that can support regulatory submissions and potential commercialization either independently or with collaborators.

As a publicly listed company on U.S. markets, I-Mab communicates clinical progress and corporate developments through regulatory filings and public disclosures. Investors and industry observers typically monitor its clinical milestones, regulatory interactions and partnership activity as indicators of the company’s development trajectory. I couldn’t find enough reliable public information to provide detailed leadership names or an exhaustive list of individual product candidates without risking inaccuracy.

Key Stats

• Today's Range: $1.77 to $1.82
• 50-Day Range: $1.60 to $2.14
• 52-Week Range: $1.46 to $6.79
• Volume: 71,259 shs
• Average Volume: 281,267 shs
• Market Capitalization: $208.17 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Hold

I-Mab Stock Analysis - MarketRank™

I-Mab scored higher than 29% of companies evaluated by MarketBeat, and ranked 752nd out of 912 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

I-Mab has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

I-Mab has a consensus price target of $9.00, representing about 400.0% upside from its current price of $1.80.

Amount of Analyst Coverage

I-Mab has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for I-Mab are expected to decrease in the coming year, from ($0.30) to ($0.67) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of I-Mab is -5.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of I-Mab is -5.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

I-Mab has a P/B Ratio of 1.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.08% of the float of I-Mab has been sold short.

Short Interest Ratio / Days to Cover

I-Mab has a short interest ratio ("days to cover") of 20.32, which indicates bearish sentiment.

Change versus previous month

Short interest in I-Mab has recently increased by 1.25%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

I-Mab does not currently pay a dividend.

Dividend Growth

I-Mab does not have a long track record of dividend growth.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: -0.52

News Sentiment

I-Mab has a news sentiment score of -0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for I-Mab this week, compared to 2 articles on an average week.

Search Interest

Only 2 people have searched for NBP on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

MarketBeat Follows

1 people have added I-Mab to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.9 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, I-Mab insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,190.00 in company stock.

Percentage Held by Insiders

22.10% of the stock of I-Mab is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

38.38% of the stock of I-Mab is held by institutions.

Company Calendar

• Last Earnings: 8/20/2026
• Today: 9/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:NBP
• CIK: 1778016
• Web: i-mabbiopharma.com
• Phone: (301) 670-2800
• Fax: N/A
• Employees: 380
• Year Founded: 2016

Price Target and Rating

• Average Price Target for I-Mab: $9.00
• High Price Target: $9.00
• Low Price Target: $9.00
• Potential Upside/Downside: +400.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.64
• Quick Ratio: 8.09

Sales & Book Value

• Annual Sales: $3.89 million
• Price / Sales: 53.51
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.74 per share
• Price / Book: 1.03

Miscellaneous

• Outstanding Shares: 115,650,000
• Free Float: 90,091,000
• Market Cap: $208.17 million
• Optionable: N/A
• Beta: 1.50